Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

This is an interventional (category 2), prospective, multicentric cohort study designed to demonstrate that the search, based on Circulating tumour DNA analysis, for a BRCA1/2 reversion mutation leading to restoration of its protein function enables early identification of disease progression in BRCA1/2 mutant patients treated as first-line maintenance with a PARP inhibitor (Olaparib alone or in combination with bevacizumab) for ovarian cancer. For this study, a total of 9 blood samples will be taken from patients who will undergo a full 24-month treatment regimen. Apart from the study proce

Trial Details

NCT ID
NCT06588322
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Blood samples will be taken on several times (36 mL of blood taken at each time):
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046
  • Limoges, France|45.83362,1.24759
  • Nîmes, France|43.83665,4.35788
  • Saint-Herblain, France|47.21154,-1.651

Key Eligibility Criteria

  • Patient with an epithelial ovarian cancer, fallopian tube cancer or primitive of the peritoneum.
  • Patient with a BRCA 1 or 2 somatic and/or constitutional mutation previously confirmed and validated by an approved laboratory.
  • Patient due to start first-line maintenance treatment with Olaparib alone (PARP inhibitor) or in combination with bevacizumab.
  • Age ≥ 18 years at the time of signing the consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →